ArticleArchives of women's mental health2022
Screening for anxiety disorders in third trimester pregnancy: a comparison of four brief measures.
Article in Archives of women's mental health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults.The Cochrane database of systematic reviews · 2025Pooled it
- Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA · 2023Pooled it
- Validating the Depression Anxiety Stress Scales-21 in Community Mothers and Fathers Across the Infant's First Year.Child: care, health and development · 2025Article
- Association between the intake of potentially risky beverages and the occurrence of endometrial polyps: a case-control study.Frontiers in nutrition · 2025Article
- Turkish adaptation of the antenatal risk questionnaire-revised: study of validity and reliability.BMC psychology · 2024Article
- Current policy and practice for the identification, management, and treatment of postpartum anxiety in the United Kingdom: a focus group study.BMC psychiatry · 2024Article
- Evaluation of perinatal anxiety assessment measures: a cognitive interview study.BMC pregnancy and childbirth · 2024Article
- Perinatal anxiety disorders screening study: a study protocol.BMC psychiatry · 2024Article
- The impact of prenatal mental health on birth outcomes before and during the COVID-19 pandemic in Anhui, China.PloS one · 2024Article
- Postpartum experiences among individuals with suspected and confirmed prenatal generalized anxiety disorder during the COVID-19 pandemic: Implications for help-seeking.Psychiatry research · 2023Article
- Pregnant Women's Anxiety and Depression Symptoms and Influence Factors in the COVID-19 Pandemic in Changzhou, China.Frontiers in psychology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence regarding the accuracy of existing anxiety screeners used in pregnancy is limited. This study compares the psychometric characteristics of the Generalized Anxiety Disorder 2- and 7-item Scales (GAD-2 and GAD-7), the anxiety subscale of the Edinburgh Postnatal Depression Scale (EPDS-3A) and the two anxiety items of the Antenatal Risk Questionnaire (ANRQ-2A). Nine hundred fifty-four women completed the screening measures and anxiety modules of a diagnostic reference standard (SAGE-SR) in the third trimester. Test performance characteristics of each measure was assessed using Receiver Operator Characteristic (ROC) analysis. We applied four previously recommended criteria to ascertain the value of each measure for widespread clinical use: area under the curve (AUC ≥ 0.8, Youden's index ≥ 0.5, negative predictive value (NPV) ≥ 0.8 and positive likelihood ratio (LR +) ≥ 4.0). Prevalence for any SAGE-SR anxiety disorder was 3%. All measures yielded an acceptable AUC of ≥ 0.8, Youden's index of ≥ 0.5 and NPV of ≥ 0.8. Only the EPDS-3A, at a cut-point ≥ 5, also achieved a LR + of ≥ 4.0 (4.35) but at this cut-point sensitivity was less than 0.75. The ANRQ-2A, at its optimal cut-point of ≥ 6, was the only measure to additionally attain both a sensitivity and specificity of ≥ .75. This study expands the evidence base for brief anxiety screening measures in the maternity setting and provides empirical support for the use of the EPDS-3A and ANRQ-2A in routine screening programmes. Studies assessing the performance of these measures in samples with higher disease prevalence and broader socio-economic status are warranted.
Indexed as
Identifiers
34350480What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.